CHICAGO -- Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with the AKT inhibitor ipatasertib added to fulvestrant after first-line CDK4/6 ...
Chemotherapy-free survival in HR-positive HER2-negative breast cancer: CDK4/6 inhibitors combination vs. endocrine monotherapy. Real-world data on the effectiveness and toxicity of CDK 4/6 inhibitors ...
GLP-1 receptor agonists (GLP-1Ras) significantly outperformed Aspirin (acetylsalicylic acid) in reducing the risk of colorectal cancer, regardless of a patient’s weight or diabetes status, according ...
The October 2024 approval of inavolisib for advanced breast cancer spotlighted a growing problem in breast oncology: Managing the hyperglycemia caused by phosphoinositide 3-kinase (PI3K)/Akt pathway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback